TDMS Study 88124-04 Pathology Tables
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
FINAL#2, 2 YEAR CHRONIC MICE
Facility: Battelle Northwest
Chemical CAS #: 22398-80-7
Lock Date: 10/02/98
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Accidently Killed 1 1
Moribund Sacrifice 4 31 15 18
Natural Death 3 6 2 10
Survivors
Terminal Sacrifice 42 13 33 21
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (47) (47) (50) (48)
Leiomyosarcoma 1 (2%)
Intestine Small, Jejunum (46) (49) (49) (44)
Carcinoma 1 (2%)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 4 (8%) 13 (26%) 7 (14%) 8 (16%)
Hepatocellular Carcinoma, Multiple 2 (4%) 4 (8%) 1 (2%) 2 (4%)
Hepatocellular Adenoma 12 (24%) 6 (12%) 12 (24%) 10 (20%)
Hepatocellular Adenoma, Multiple 8 (16%) 6 (12%) 4 (8%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Mesentery (13) (8) (8) (4)
Carcinoma, Metastatic, Uncertain Primary Site 1 (13%)
Sarcoma 1 (8%)
Pancreas (50) (49) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Salivary Glands (49) (50) (50) (50)
Stomach, Forestomach (50) (49) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (49) (49) (50) (49)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (49) (49) (50) (49)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Benign 2 (4%) 2 (4%)
Islets, Pancreatic (50) (49) (50) (50)
Adenoma 2 (4%)
Pituitary Gland (50) (50) (48) (49)
Carcinoma 1 (2%)
Pars Distalis, Adenoma 10 (20%) 7 (14%) 11 (23%) 7 (14%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (49) (50) (49)
Bilateral, Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Carcinoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (47) (46) (44) (47)
Carcinoma, Metastatic, Uterus 1 (2%)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Benign 2 (5%)
Histiocytic Sarcoma 1 (2%)
Teratoma Malignant 1 (2%)
Uterus (50) (49) (50) (50)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 2 (4%)
Polyp Stromal, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (1) (5) (6) (8)
Renal, Histiocytic Sarcoma 1 (20%) 1 (13%)
Lymph Node, Bronchial (36) (50) (48) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Lymph Node, Mandibular (36) (36) (43) (42)
Histiocytic Sarcoma 1 (3%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (48) (49) (50) (48)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Lymph Node, Mediastinal (42) (48) (46) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Spleen (50) (49) (50) (49)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Thymus (47) (46) (42) (42)
Histiocytic Sarcoma 2 (4%) 2 (5%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 2 (4%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Skeletal Muscle (1)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spinal Cord (1) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 6 (12%) 9 (18%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 5 (10%) 5 (10%) 7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (2) (2)
Adenoma 2 (67%) 2 (100%) 2 (100%)
Adenoma, Multiple 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
Urinary Bladder (48) (49) (49) (48)
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 3 (6%) 1 (2%) 3 (6%)
Lymphoma Malignant 8 (16%) 4 (8%) 10 (20%) 13 (26%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 37 45 40
Total Primary Neoplasms 56 65 80 74
Total Animals with Benign Neoplasms 25 24 36 26
Total Benign Neoplasms 31 29 52 35
Total Animals with Malignant Neoplasms 20 25 25 27
Total Malignant Neoplasms 25 36 28 39
Total Animals with Metastatic Neoplasms 1 2 5 3
Total Metastatic Neoplasm 1 6 11 6
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Natural Death 8 11 9 11
Moribund Sacrifice 5 14 12 12
Accidently Killed 1
Survivors
Terminal Sacrifice 37 24 29 27
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (43) (43) (42) (44)
Adenoma 1 (2%) 1 (2%)
Intestine Small, Jejunum (47) (44) (46) (44)
Adenoma 1 (2%)
Carcinoma 1 (2%) 3 (7%) 2 (5%)
Peyer's Patch, Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (45) (47) (43) (45)
Carcinoma 2 (5%) 1 (2%)
Peyer's Patch, Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 10 (20%) 15 (30%) 13 (26%) 11 (22%)
Hepatocellular Carcinoma, Multiple 1 (2%) 7 (14%) 10 (20%) 5 (10%)
Hepatocellular Adenoma 9 (18%) 11 (22%) 13 (26%) 18 (36%)
Hepatocellular Adenoma, Multiple 8 (16%) 13 (26%) 10 (20%) 14 (28%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mesentery (4) (5) (5) (8)
Fat, Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (13%)
Fat, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (13%)
Pancreas (50) (50) (49) (47)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (49) (50) (48) (50)
Squamous Cell Carcinoma 1 (2%)
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (48) (50)
Adenoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (50) (48) (49)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (49) (47)
Adenoma 2 (4%)
Adenoma, Multiple 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Pituitary Gland (48) (47) (45) (50)
Pars Intermedia, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (47) (48) (47) (50)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Preputial Gland (50) (50) (50) (49)
Prostate (50) (49) (48) (48)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (1) (1) (1) (2)
Pancreatic, Histiocytic Sarcoma 1 (100%)
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Bronchial (35) (48) (45) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (28) (32) (33) (36)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (48) (47) (49) (45)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (40) (49) (45) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 2 (4%) 1 (2%)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Spleen (50) (50) (48) (48)
Hemangiosarcoma 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (35) (39) (41) (35)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (49) (50) (50)
Oligodendroglioma Malignant, Metastatic,
Brain 1 (2%)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (2)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
Sarcoma 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 12 (24%) 7 (14%) 7 (14%) 10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 7 (14%) 19 (38%) 9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 8 (16%) 3 (6%) 4 (8%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 1 (2%) 6 (12%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 2 (4%) 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skeletal
Muscle 1 (2%)
Nose (49) (50) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1) (3) (2)
Adenoma 1 (100%) 2 (67%) 1 (50%)
Adenoma, Multiple 1 (50%)
Carcinoma 1 (100%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (50) (48) (47)
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 88124-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 02/24/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:06:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 45 46 45
Total Primary Neoplasms 66 83 98 90
Total Animals with Benign Neoplasms 29 27 31 35
Total Benign Neoplasms 40 36 42 49
Total Animals with Malignant Neoplasms 21 35 40 30
Total Malignant Neoplasms 26 47 56 41
Total Animals with Metastatic Neoplasms 6 3 10 7
Total Metastatic Neoplasm 8 4 16 20
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 73979-73979/73979
--multipart-boundary--